These data suggest that ALDH+CD44+CXCR4+CD24+-cell-derived tumours may be less sensitive to androgen deprivation/antiandrogen therapy than those derived from ALDH−CD44−CXCR4−CD24− cells. This evidence concerns the gene CXCR4 and neoplasm.